Most Recent

image: Contributors

Contributors

By | January 1, 2017

Meet some of the people featured in the January 2017 issue of The Scientist.

0 Comments

image: Pharma Redo

Pharma Redo

By | January 1, 2017

Steve Braun of Cures Within Reach, a nonprofit focused on breathing new life into old medicines, describes the potential benefits of drug repurposing.

1 Comment

image: Repurposing Existing Drugs for New Indications

Repurposing Existing Drugs for New Indications

By | January 1, 2017

An entire industry has sprung up around resurrecting failed drugs and recycling existing compounds for novel indications.

1 Comment

image: Infographic: Repurposing Strategies

Infographic: Repurposing Strategies

By | January 1, 2017

Novel uses for existing and failed drugs may save companies time and money in bringing new therapeutics to market.

0 Comments

image: Life Science Controversies of 2016

Life Science Controversies of 2016

By , , and | December 23, 2016

This year, the developers of CRISPR gene-editing technology argued over patent rights, a researcher fought to unmask anonymous PubPeer commenters, US regulators considered “three-parent” babies, and troubles continued for Theranos.

0 Comments

Oncologists have raised concerns about a mouse study that suggests the vaccine for human papillomavirus could cause brain damage.

0 Comments

image: Video: Patent Battle Over CRISPR Gene Editing

Video: Patent Battle Over CRISPR Gene Editing

By | December 13, 2016

The Scientist goes to court for a CRISPR patent interference case at the US Patent and Trademark Office.

0 Comments

image: New Developments in CRISPR Patent Case

New Developments in CRISPR Patent Case

By | December 12, 2016

Documents suggest Feng Zhang started working on CRISPR before Jennifer Doudna’s group published; researchers call for CRISPR technology to be shared openly

0 Comments

image: CRISPR Oral Arguments Recap, Cont’d

CRISPR Oral Arguments Recap, Cont’d

By | December 8, 2016

This week’s CRISPR patent hearing took a deep dive into the science of moving the gene-editing technology from prokaryotes to eukaryotic systems.

2 Comments

image: USPTO to Hear Arguments on CRISPR Patents

USPTO to Hear Arguments on CRISPR Patents

By | December 5, 2016

Tuesday morning, the US Patent and Trademark Office will hear oral arguments from the two parties that claim to have been the first to use CRISPR-Cas9 gene editing technology in eukaryotic cells.

0 Comments

Popular Now

  1. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  2. Authors Peeved by APA’s Article Takedown Pilot
  3. Athletes’ Microbiomes Differ from Nonathletes
  4. Was a Drop in CRISPR Firms’ Stock Warranted?
AAAS